Andexxa

Andexxa (also known as andexanet alfa) is a medication used as a reversal agent for certain anticoagulants. It is specifically designed to counteract the effects of Factor Xa inhibitors, such as apixaban and rivaroxaban. Andexxa is a recombinant modified human Factor Xa decoy protein that binds to Factor Xa inhibitors, thereby neutralizing their anticoagulant effects.

Medical Uses

Andexxa is primarily used in cases of life-threatening or uncontrolled bleeding in patients who are taking Factor Xa inhibitors. It is administered intravenously and works by sequestering the Factor Xa inhibitors, allowing the body's natural coagulation process to resume.

Mechanism of Action

Andexxa acts as a decoy for Factor Xa inhibitors. By mimicking the structure of native Factor Xa, it binds to the inhibitors with high affinity, preventing them from inhibiting the actual Factor Xa in the blood. This restores the normal clotting process, which is crucial in managing severe bleeding events.

Approval and Regulation

Andexxa was approved by the U.S. Food and Drug Administration (FDA) in May 2018. It is also approved by the European Medicines Agency (EMA) under the trade name Ondexxya. The approval was based on clinical trials that demonstrated its efficacy in reversing the anticoagulant effects of Factor Xa inhibitors.

Side Effects

Common side effects of Andexxa include infusion-related reactions, such as flushing, fever, and chills. There is also a risk of thromboembolic events, as the reversal of anticoagulation can lead to the formation of blood clots.

Administration

Andexxa is administered as an intravenous bolus followed by a continuous infusion. The dosage and duration of administration depend on the specific Factor Xa inhibitor being reversed and the severity of the bleeding.

Related Pages

• Factor Xa inhibitors
• Apixaban
• Rivaroxaban
• Anticoagulant
• Thromboembolism
• U.S. Food and Drug Administration
• European Medicines Agency

See Also

• Reversal agents
• Hemostasis
• Coagulation